Such is Lilly Miller’s passion for thoroughbreds, she even spent her recent ‘holiday’ riding horses in the Victorian countryside. But like all stable hands who rise from their beds in the early hours ...

Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints.

Eli Lilly (LLY) announced it is cutting prices of its blockbuster weight-loss drug Zepbound after less than a year on the market. The company is pricing its 2.5mg doses at $399 per month and 5mg ...

Lilly’s campus in Cork has quadrupled its head count since 2019, with more than 2,000 employees expected by the end of 2024, more than half of whom are working in clinical R&D. The funding for ...

Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.

Eli Lilly is announcing a new way to get its popular Zepbound drug. People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of ...

For context, the drug originally launched last year at a list price of $1,059, which Lilly said was approximately 20% lower than Novo Nordisk’s competing semaglutide products. Novo’s obesity ...

On Tuesday, Pfizer (PFE) said it will enter the direct-to-consumer business, following the lead of a Big Pharma rival, Eli Lilly (LLY), which launched a similar plan in January. The new website ...

Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect. With a doctors ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more affordable ...

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. By Dani Blum With high demand for drugs ...